melatonin and Parkinson Disease studies

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

Excerpt	Relevance	Reference
"To determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics."	7.80	Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. ( Marconi, A; Noble, C; Peng, J; Rademaker, AW; Reid, KJ; Simuni, T; Turek, FW; Videnovic, A; Zadikoff, C; Zee, PC, 2014)
"Using salivary dim light melatonin onset (DLMO) and actigraphy, our study sought to determine if Parkinson disease (PD) patients demonstrate circadian disturbance compared to healthy controls."	7.80	Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. ( Bolitho, SJ; Grunstein, RR; Hodges, JR; Lewis, SJ; Naismith, SL; Rajaratnam, SM; Rogers, N; Terpening, Z, 2014)
"In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly."	7.01	Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023)
"Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems."	6.72	Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021)
"The prevention of neurodegenerative disorders has become an emerging public health challenge for our society."	6.66	Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020)
"Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects."	6.66	Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020)
"Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke."	6.43	Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005)
"Nocturia is one of the commonest non-motor symptoms in Parkinson's disease (PD)."	5.62	Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease. ( Baldwin, J; Batla, A; Bhatia, KP; deMin, L; Eriksson, S; Islam, S; Melbourne, C; Pakzad, M; Panicker, JN; Simeoni, S; Uchiyama, T, 2021)
"A MEDLINE search (1977-April 2007) using the terms REM sleep behavior disorder, narcolepsy, parkinsonian disorders, levodopa, dopamine agonists, clonazepam, benzodiazepines, and melatonin was used to retrieve relevant articles."	4.84	Rapid eye movement sleep behavior disorder. ( Gugger, JJ; Wagner, ML, 2007)
"Objective To investigate the changes of serum melatonin(MLT)and glutathione(GSH)levels in patients with Parkinson's disease(PD)and explore their relationships with disease severity,cognitive dysfunction,and sleep disorders."	3.91	[Correlations of Melatonin and Glutathione Levels with Oxidative Stress Mechanism in Parkinson's Disease]. ( Bai, HY; DU, M; Wei, HJ, 2019)
"To determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics."	3.80	Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. ( Marconi, A; Noble, C; Peng, J; Rademaker, AW; Reid, KJ; Simuni, T; Turek, FW; Videnovic, A; Zadikoff, C; Zee, PC, 2014)
"Using salivary dim light melatonin onset (DLMO) and actigraphy, our study sought to determine if Parkinson disease (PD) patients demonstrate circadian disturbance compared to healthy controls."	3.80	Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. ( Bolitho, SJ; Grunstein, RR; Hodges, JR; Lewis, SJ; Naismith, SL; Rajaratnam, SM; Rogers, N; Terpening, Z, 2014)
" Mild adverse events were reported in three patients in the clonazepam, two patients in the trazodone group, and none in the melatonin group."	3.11	Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. ( Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S, 2022)
"Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects."	3.01	Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson's Disease. ( Cid-Hernández, M; Cruz-Serrano, JA; Delgado-Lara, DL; González-Ortiz, LJ; González-Usigli, HA; Jiménez-Delgado, A; Ortiz, GG; Pacheco-Moisés, FP, 2021)
"In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly."	3.01	Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023)
"Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide."	3.01	Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association. ( Esmaeili, A; Ghasemnejad-Berenji, M; Khezri, MR, 2023)
"Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime."	2.94	Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. ( Coeytaux Jackson, A; Fang, BAM; Gilat, M; Grunstein, RR; Hall, JM; Hammond, D; Lewis, SJG; Marshall, NS; Mullins, AE; Wong, KKH; Yee, BJ, 2020)
"Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes."	2.94	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease. ( Cárdenas-Bedoya, J; Cruz-Serrano, JA; de la Rosa, AC; Delgado-Lara, DL; González-Enríquez, GV; González-Usigli, H; Jiménez-Delgado, A; Macías-Islas, MA; Ortiz, GG; Pacheco-Moisés, F; Torres-Mendoza, BM, 2020)
"We studied 38 patients with Parkinson's disease (PD) without dementia (mean age, 67."	2.77	[Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam]. ( Krasakov, IV; Litvinenko, IV; Tikhomirova, OV, 2012)
"Melatonin has been shown to improve sleep in several conditions."	2.73	Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. ( Carvalhedo de Bruin, PF; de Bruin, VM; de Lourdes Seabra, M; Lopes, LA; Magalhães, MC; Medeiros, CA, 2007)
"Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems."	2.72	Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021)
"Many patients with Parkinson's disease (PD) experience sleep-related symptoms."	2.71	Melatonin for sleep disturbances in Parkinson's disease. ( Aminoff, MJ; Carter, JH; Colling, E; Dowling, GA; Mastick, J; Singer, CM, 2005)
"The prevention of neurodegenerative disorders has become an emerging public health challenge for our society."	2.66	Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020)
"Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects."	2.66	Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020)
"In amyotrophic lateral sclerosis and Huntington's disease, WNT/beta-catenin pathway is upregulated, whereas PPAR gamma is downregulated."	2.58	Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. ( Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN, 2018)
"Patients with rapid eye movement sleep behavior disorder are frequently prone to sleep-related injuries and should be treated to prevent injury with either melatonin 3-12 mg or clonazepam 0."	2.55	REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. ( Boeve, AR; Boeve, BF; St Louis, EK, 2017)
"Melatonin acts as a free-radical scavenger, reducing reactive species and improving mitochondrial homeostasis."	2.53	Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. ( Fernandes, PA; Mack, JM; Markus, RP; Pértile, RA; Prediger, RD; Sampaio, TB; Schamne, MG, 2016)
"The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism."	2.50	Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014)
"For more than 50 years, Parkinson's disease (PD) has been conceptualized as a product of nigro-striatal dopamine (NSD) system degeneration."	2.44	Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. ( Willis, GL, 2008)
"Melatonin is a hormone with indolaminic structure, produced in the pineal gland during darkness, with chronobiological activity that has been known for decades."	2.44	[Melatonina: old molecule, new medicament]. ( Fernández-Tresguerres Hernández, JA, 2008)
"Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke."	2.43	Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005)
"Melatonin has been shown to prevent the progressive degeneration produced by neurotoxins employed in experimental models to mimic the degenerative events in various neuropsychiatric disease states."	2.43	The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. ( Willis, GL, 2005)
" Moreover, in animal models, interventions that increase the bioavailability of melatonin appears to increase the severity of parkinsonian symptoms, whereas reduction in melatonin by pinealectomy or exposure to bright light can enhance recovery from parkinsonisms symptoms."	2.43	Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? ( Chen, H; Ritz, B; Schernhammer, E, 2006)
"Barbeau hypothesized that Parkinson's disease is associated with hypothalamic deficiency of the specialized neuroendocrine cell system (A."	2.38	Pineal melatonin functions: possible relevance to Parkinson's disease. ( Sandyk, R, 1990)
"Parkinson's disease is a progressive neurodegenerative movement disorder."	1.91	The effects of regular swimming exercise and melatonin on the neurons localized in the striatum of hemiparkinsonian rats. ( Boracı, H; Gergin, S; Kirazlı, Ö; Şehirli, ÜS; Yananlı, HR; Yıldız, SD, 2023)
"Melatonin has been shown to improve sleep in PD patients."	1.72	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence. ( Cerroni, R; Fernandes, M; Liguori, C; Ludovisi, R; Mercuri, NB; Pierantozzi, M; Stefani, A, 2022)
"Melatonin is a potent antioxidant that has the beneficial ability to prevent neurodegenerative diseases like PD."	1.72	Melatonin attenuates MPP ( Choi, H; Jung, YJ; Oh, E, 2022)
"Parkinson's disease was induced in rats using neurotoxin 6-Hydroxydopamine."	1.72	The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease. ( Abbaszadeh, HA; Abdollahifar, MA; Aliaghaei, A; Asemi-Rad, A; Ebrahimi, MJ; Heidari, MH; Moafi, M; Sadeghi, Y, 2022)
"Nocturia is one of the commonest non-motor symptoms in Parkinson's disease (PD)."	1.62	Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease. ( Baldwin, J; Batla, A; Bhatia, KP; deMin, L; Eriksson, S; Islam, S; Melbourne, C; Pakzad, M; Panicker, JN; Simeoni, S; Uchiyama, T, 2021)
" The multiple neuroprotective roles of dopamine and melatonin are often demonstrated separately; however, this approach suffers from low and short bioavailability and is associated with side-effects upon overdosing."	1.56	Melatonin/polydopamine nanostructures for collective neuroprotection-based Parkinson's disease therapy. ( Karmakar, S; Roy Choudhury, S; Srivastava, AK, 2020)
"People with Parkinson's disease had significantly poorer sleep quality with higher subjective sleep scores (p < 0."	1.56	Melanopsin Cell Dysfunction is Involved in Sleep Disruption in Parkinson's Disease. ( Dumpala, S; Feigl, B; Kerr, GK; Zele, AJ, 2020)
" Among PD patients, a clear and robust dose-response association was found between levodopa equivalent dose and UME, independent of potential confounding factors, including Parkinson's disease severity."	1.56	Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy. ( Kataoka, H; Kurumatani, N; Obayashi, K; Saeki, K; Sugie, K, 2020)
"Rotenone is a frequently used neurotoxin in developing a PD model to aid in understanding the mechanisms of neuronal death."	1.48	Melatonin Improves Behavioral and Biochemical Outcomes in a Rotenone-Induced Rat Model of Parkinson's Disease. ( Andrabi, SS; Parveen, S; Parvez, S; Rasheed, MZ; Salman, M; Shaquiquzzaman, M; Tabassum, H, 2018)
"Circadian disturbances-related to Parkinson's disease are reviewed and possible pathogenetic mechanisms are discussed."	1.43	[Circadian Regulation and Its Disorders in Parkinson's Disease Patients. Part 2. Experimental Models, Alpha-Synuclein and Melatonin.] ( Kovalzon, VM; Ukraintseva, YV, 2016)
"Melatonin is a chronobiotic treatment which also alleviates rapid eye movement (REM) sleep behavior disorder (RBD)."	1.43	Loss of REM sleep features across nighttime in REM sleep behavior disorder. ( Arnaldi, D; Arnulf, I; Latimier, A; Leu-Semenescu, S; Vidailhet, M, 2016)
"Melatonin levels were significantly associated with hypothalamic gray matter volume and disease severity in PD patients."	1.43	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. ( Barker, RA; Breen, DP; Brooks, DJ; Burn, DJ; Fisher, K; Jones, PS; Nombela, C; Reddy, AB; Rowe, JB; Vuono, R, 2016)
"Treatment with melatonin at 4 mM significantly attenuated the sleep problems and rescued the reduction in mEPSC and EPSP frequency in the hLRRK2 transgenic flies."	1.43	Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a Drosophila model of Parkinson's disease. ( Chen, L; Gu, H; Guo, W; Huang, Y; Liang, F; Long, S; Lu, X; Nucifora, FC; Pei, Z; Ran, D; Ross, CA; Sun, X; Zeng, J; Zhao, X, 2016)
"Two hallmarks of Parkinson's disease (PD) are dopaminergic cell loss and the presence of cytoplasmic inclusions (Lewy bodies)."	1.39	Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. ( Baekelandt, V; Brito-Armas, JM; Castro, R; Castro-Hernández, JR; González-Hernández, T; Rodríguez, M, 2013)
"Melatonin has multiple roles including neuroprotection."	1.34	Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. ( McMillan, CR; Niles, LP; Sharma, R, 2007)
" These findings demonstrate that endogenous melatonin protects exogenous L-DOPA from autoxidation in the extracellular compartment of the striatum of freely moving rats; moreover, systemic co-administration of melatonin with L-DOPA markedly increases striatal L-DOPA bioavailability in control as well as in melatonin-depleted rats."	1.33	Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. ( Desole, MS; Esposito, G; Marchetti, B; Miele, E; Migheli, R; Rocchitta, G; Serra, PA, 2006)
"Data from 12 early Parkinson's disease (PD) and 9 advanced PD patients were compared with those from 13 age-matched healthy controls."	1.31	Increased pineal Fdopa uptake is related to severity of Parkinson's disease--a PET study. ( Ghaemi, M; Heiss, WD; Herholz, K; Hilker, R; Rudolf, J, 2001)
" These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD."	1.30	A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999)
"Stage and duration of Parkinson's disease did not correlate with the amount of secreted melatonin."	1.29	Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. ( Auff, E; Doppelbauer, A; Fertl, E; Waldhauser, F, 1993)

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (8.06)	18.7374
1990's	23 (18.55)	18.2507
2000's	17 (13.71)	29.6817
2010's	42 (33.87)	24.3611
2020's	32 (25.81)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease[NCT02789592]	Phase 2	30 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER: Constitution of a Cohort for a Long-term Prospective Follow-up Study[NCT06140511]		600 participants (Anticipated)	Observational	2023-11-20	Not yet recruiting
Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2021-05-31	Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. Cellular and molecular biology (Noisy-le-Grand, France), 2021, Nov-25, Volume: 67, Issue:3 Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Neuroprotec	2021
Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. International journal of molecular sciences, 2023, Jan-25, Volume: 24, Issue:3 Topics: Aged; Alzheimer Disease; Antioxidants; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum St	2023
Oxidative Stress and Aging as Risk Factors for Alzheimer's Disease and Parkinson's Disease: The Role of the Antioxidant Melatonin. International journal of molecular sciences, 2023, Feb-03, Volume: 24, Issue:3 Topics: Aged; Aging; Alzheimer Disease; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Oxidati	2023
The multimodal effect of circadian interventions in Parkinson's disease: A narrative review. Parkinsonism & related disorders, 2023, Volume: 110 Topics: Circadian Rhythm; Disabled Persons; Humans; Melatonin; Motor Disorders; Parkinson Disease; Sleep	2023
Molecular mechanisms of melatonin-induced alleviation of synaptic dysfunction and neuroinflammation in Parkinson's disease: a review. European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:11 Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Humans; Inflammasomes; Melatonin; Mice; Mice,	2023
REM behavior disorder: When Parkinson's disease meets Morpheus. Revue neurologique, 2023, Volume: 179, Issue:7 Topics: Aged; Clonazepam; Humans; Melatonin; Parkinson Disease; REM Sleep Behavior Disorder; Synucleinopathi	2023
Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association. ACS chemical neuroscience, 2023, 11-01, Volume: 14, Issue:21 Topics: Alzheimer Disease; Gastrointestinal Microbiome; Humans; Melatonin; Neurodegenerative Diseases; Parki	2023
Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's disease. Behavioural pharmacology, 2019, Volume: 30, Issue:8 Topics: Animals; Anti-Inflammatory Agents; Caffeine; Cannabinoids; Dietary Supplements; Humans; Melatonin; N	2019
Antioxidants and Neuron-Astrocyte Interplay in Brain Physiology: Melatonin, a Neighbor to Rely on. Neurochemical research, 2021, Volume: 46, Issue:1 Topics: Alzheimer Disease; Animals; Antioxidants; Astrocytes; Brain; Brain Neoplasms; Cell Line, Tumor; Huma	2021
Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson's Disease. Cells, 2020, 01-28, Volume: 9, Issue:2 Topics: Brain; Circadian Rhythm; Humans; Inflammation; Melatonin; Oxidative Stress; Parkinson Disease	2020
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. Biomolecules, 2020, 08-07, Volume: 10, Issue:8 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Circadian Rhythm; Dementia, Vascular; Hum	2020
Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. International journal of molecular sciences, 2020, Sep-28, Volume: 21, Issue:19 Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Autophagy; Autophagy	2020
Sleep Issues in Parkinson's Disease and Their Management. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:4 Topics: Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Deep Brain Stimulation; Disease Management;	2020
The Isolated Form of Rapid Eye Movement Sleep Behavior Disorder: The Upcoming Challenges. Sleep medicine clinics, 2021, Volume: 16, Issue:2 Topics: Clonazepam; Dementia; Diagnostic Tests, Routine; Humans; Melatonin; Parkinson Disease; REM Sleep Beh	2021
REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:5 Topics: Central Nervous System Depressants; Clonazepam; GABA Modulators; Humans; Lewy Body Disease; Melatoni	2017
The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. Cellular and molecular life sciences : CMLS, 2017, Volume: 74, Issue:20 Topics: alpha-Synuclein; Animals; Circadian Clocks; Dopamine; Dopaminergic Neurons; Genetic Predisposition t	2017
Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. Neuromolecular medicine, 2018, Volume: 20, Issue:2 Topics: Adenosine Triphosphate; Aerobiosis; Amyotrophic Lateral Sclerosis; Brain; Circadian Rhythm; Energy M	2018
[PROTECTIVE ROLE OF MELATONIN IN ETIOLOGY AND COURSE OF PARKINSON'S DISEASE: EXPERIMENTAL EVIDENCE.] Eksperimental'naia i klinicheskaia farmakologiia, 2016, Volume: 79, Issue:9 Topics: Animals; Dopamine; Humans; Melatonin; Mitochondria; Neurons; Parkinson Disease; Sleep Initiation and	2016
REM sleep behaviour disorder. Nature reviews. Disease primers, 2018, 08-30, Volume: 4, Issue:1 Topics: alpha-Synuclein; Antidepressive Agents; Central Nervous System Depressants; Clonazepam; Diagnosis, D	2018
Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. Cellular and molecular neurobiology, 2020, Volume: 40, Issue:1 Topics: Animals; Apoptosis; Autophagy; Disease Models, Animal; Humans; Melatonin; Oxidative Stress; Parkinso	2020
Management of the aging risk factor for Parkinson's disease. Neurobiology of aging, 2014, Volume: 35, Issue:4 Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb	2014
Brain metabolism as a modulator of autophagy in neurodegeneration. Brain research, 2016, Oct-15, Volume: 1649, Issue:Pt B Topics: Alzheimer Disease; Animals; Autophagy; Brain; Cholesterol; Ghrelin; Glucose; Glycogen; Homeostasis;	2016
Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. Current pharmaceutical design, 2016, Volume: 22, Issue:40 Topics: Depression; Gastrointestinal Microbiome; Humans; Inflammation; Intestinal Mucosa; Intestines; Melato	2016
Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. Oxidative medicine and cellular longevity, 2016, Volume: 2016 Topics: Humans; Melatonin; Neuroprotection; Parkinson Disease	2016
Sleep and Neurodegeneration: A Critical Appraisal. Chest, 2017, Volume: 151, Issue:6 Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Melatonin; Multiple System Atrophy; Neurodeg	2017
Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Reviews in the neurosciences, 2008, Volume: 19, Issue:4-5 Topics: Animals; Circadian Rhythm; Dopamine; Endocrine System Diseases; Humans; Melatonin; Nerve Degeneratio	2008
[Melatonina: old molecule, new medicament]. Anales de la Real Academia Nacional de Medicina, 2008, Volume: 125, Issue:4 Topics: Administration, Oral; Age Factors; Aged; Alzheimer Disease; Animals; Antioxidants; Central Nervous S	2008
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. The Journal of neuropsychiatry and clinical neurosciences, 2010,Winter, Volume: 22, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo	2010
[Melatonin: its role in the system of neurohumoral regulation in man. Part 2]. Klinicheskaia meditsina, 2011, Volume: 89, Issue:2 Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Anticarcinogenic Agents; Blood Pressure; Cardiova	2011
Melatonin and mitochondrial dysfunction in the central nervous system. Hormones and behavior, 2013, Volume: 63, Issue:2 Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Melatonin; Mitochondria; Parkinson Disease	2013
[REM sleep behavior disorder (RBD)]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:15 Topics: Clonazepam; Diagnosis, Differential; GABA Modulators; Humans; Melatonin; Parkinson Disease; Polysomn	2012
Fluctuations in cognition and alertness in Parkinson's disease and dementia. Neurology, 2004, Oct-26, Volume: 63, Issue:8 Suppl 3 Topics: Awareness; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition Disorders; Dement	2004
Role of melatonin in neurodegenerative diseases. Neurotoxicity research, 2005, Volume: 7, Issue:4 Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Brain Chemistry; Brain Injuries; Free Radical Scave	2005
Melatonin and Parkinson's disease. Endocrine, 2005, Volume: 27, Issue:2 Topics: Animals; Apoptosis; Free Radical Scavengers; Free Radicals; Humans; Inflammation; Melatonin; Mitocho	2005
The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug news & perspectives, 2005, Volume: 18, Issue:7 Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Melato	2005
Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer causes & control : CCC, 2006, Volume: 17, Issue:4 Topics: Animals; Humans; Melatonin; Neoplasms; Parkinson Disease; Risk Factors	2006
Rapid eye movement sleep behavior disorder. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:11 Topics: Anticonvulsants; Antiparkinson Agents; Benzothiazoles; Clonazepam; Comorbidity; Dopamine Agonists; G	2007
Catecholamine systems of retina: a model for studying synaptic mechanisms. Life sciences, 1984, Sep-10, Volume: 35, Issue:11 Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Darkness; Dopamine; Ele	1984
Weak electromagnetic fields reverse visuospatial hemi-inattention in Parkinson's disease. The International journal of neuroscience, 1995, Volume: 81, Issue:1-2 Topics: Aged; Brain; Cognition Disorders; Electromagnetic Phenomena; Functional Laterality; Humans; Male; Me	1995
Improvement in word-fluency performance in Parkinson's disease by administration of electromagnetic fields. The International journal of neuroscience, 1994, Volume: 77, Issue:1-2 Topics: Aged; Cerebral Ventricles; Dopamine; Electromagnetic Fields; Female; Frontal Lobe; Humans; Male; Mel	1994
The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion. The International journal of neuroscience, 1997, Volume: 90, Issue:3-4 Topics: Aging; Alzheimer Disease; Circadian Rhythm; Dopamine; Humans; Melatonin; Middle Aged; Parkinson Dise	1997
Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision research, 1997, Volume: 37, Issue:24 Topics: Aging; Animals; Dopamine; Humans; Mammals; Melatonin; Parkinson Disease; Retina; Retinal Degeneratio	1997
Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cellular and molecular neurobiology, 2001, Volume: 21, Issue:6 Topics: Animals; Biological Clocks; Circadian Rhythm; Dopamine; Dyskinesia, Drug-Induced; Humans; Hypothalam	2001
The pineal gland: a review of the biochemistry, physiology and pharmacological potential of melatonin and other pineal substances. Advances in drug research, 1977, Volume: 11 Topics: Animals; Brain; Brain Diseases; Brain Neoplasms; Calcinosis; Circadian Rhythm; Endocrine Glands; Epi	1977
Magnetic fields in the therapy of parkinsonism. The International journal of neuroscience, 1992, Volume: 66, Issue:3-4 Topics: Aged; Brain; Brain Diseases; Cognition Disorders; Dopamine; Electromagnetic Fields; Female; Function	1992
Pineal melatonin functions: possible relevance to Parkinson's disease. The International journal of neuroscience, 1990, Volume: 50, Issue:1-2 Topics: Animals; Humans; Melatonin; Parkinson Disease; Pineal Gland	1990
Mechanisms of action of ECT in Parkinson's disease: possible role of pineal melatonin. The International journal of neuroscience, 1990, Volume: 50, Issue:1-2 Topics: Electroconvulsive Therapy; Humans; Melatonin; Parkinson Disease; Pineal Gland	1990
Pineal melatonin and sensory symptoms in Parkinson disease. Italian journal of neurological sciences, 1989, Volume: 10, Issue:4 Topics: Animals; Humans; Melatonin; Neurons, Afferent; Pain; Parkinson Disease; Pineal Gland; Serotonin	1989
Melatonin: effects on brain function. Advances in biochemical psychopharmacology, 1974, Volume: 11, Issue:0 Topics: Adenylyl Cyclases; Aminobutyrates; Animals; Behavior; Brain; Cerebral Cortex; Cyclic AMP; Electric S	1974
Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annual review of medicine, 1971, Volume: 22 Topics: Animals; Brain; Choline; Chronic Disease; Dihydroxyphenylalanine; Drug Synergism; Humans; Manganese	1971

Article	Year
Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson's Disease. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Antioxidants; Antiparkinson Agents; Biomarkers; Cell Respiration; Cross-Over Studies; Double-Blind M	2021
Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:10 Topics: Clonazepam; Double-Blind Method; Humans; Iran; Melatonin; Parkinson Disease; Sleep Wake Disorders; T	2022
Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:2 Topics: Aged; Clonazepam; Double-Blind Method; Eye Movements; Fatigue; Female; Humans; Male; Melatonin; Midd	2020
Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clinical neurology and neurosurgery, 2020, Volume: 195 Topics: Aged; Aged, 80 and over; Antioxidants; Double-Blind Method; Female; Humans; Male; Melatonin; Middle	2020
Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial. Parkinsonism & related disorders, 2020, Volume: 75 Topics: Adult; Central Nervous System Depressants; Circadian Rhythm; Delayed-Action Preparations; Double-Bli	2020
Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129 Topics: Adult; Aged; ARNTL Transcription Factors; Cross-Over Studies; Double-Blind Method; Female; Gene Expr	2020
[The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:7 Pt 2 Topics: Central Nervous System Depressants; Chronobiology Disorders; Circadian Rhythm; Dose-Response Relatio	2013
[Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2012, Volume: 112, Issue:12 Topics: Aged; Antioxidants; Clonazepam; Drug Therapy, Combination; Female; Humans; Male; Melatonin; Middle A	2012
Melatonin-controlled release - neurim pharmaceuticals. Circadin, melatonin-prolonged release, melatonin-sustained release. Drugs in R&D, 2003, Volume: 4, Issue:2 Topics: Administration, Oral; Age Factors; Delayed-Action Preparations; Drugs, Investigational; Dyskinesia,	2003
Melatonin for sleep disturbances in Parkinson's disease. Sleep medicine, 2005, Volume: 6, Issue:5 Topics: Adult; Aged; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Met	2005
Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. Journal of neurology, 2007, Volume: 254, Issue:4 Topics: Adult; Aged; Analysis of Variance; Antioxidants; Double-Blind Method; Female; Humans; Male; Melatoni	2007
Circadian secretion pattern of melatonin in Parkinson's disease. Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:1 Topics: Adult; Aged; Biomarkers; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; P	1991
Melatonin and parkinsonism. Lancet (London, England), 1973, Feb-03, Volume: 1, Issue:7797 Topics: Administration, Oral; Aged; Clinical Trials as Topic; Female; Humans; Male; Melatonin; Middle Aged;	1973

Article	Year
Imaging of cerebral tryptophan metabolism using 7-[ NeuroImage, 2022, 02-15, Volume: 247 Topics: Animals; Disease Models, Animal; Fluorine Radioisotopes; Hippocampus; Kynurenine; Male; Melatonin; O	2022
Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:9 Topics: Disabled Persons; Humans; Melatonin; Motor Disorders; Parkinson Disease; Pilot Projects; Quality of	2022
Melatonin attenuates MPP Biochemical and biophysical research communications, 2022, 09-17, Volume: 621 Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Line, Tumor; Dopaminergic Neurons; Heat-Shock Proteins;	2022
The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease. Metabolic brain disease, 2022, Volume: 37, Issue:8 Topics: Animals; Cell Death; Dopaminergic Neurons; Glutathione; Melatonin; Neurodegenerative Diseases; Oxida	2022
The effects of regular swimming exercise and melatonin on the neurons localized in the striatum of hemiparkinsonian rats. Anatomical science international, 2023, Volume: 98, Issue:2 Topics: Animals; Male; Melatonin; Neurons; Oxidopamine; Parkinson Disease; Physical Conditioning, Animal; Ra	2023
Melatonin/polydopamine nanostructures for collective neuroprotection-based Parkinson's disease therapy. Biomaterials science, 2020, Mar-07, Volume: 8, Issue:5 Topics: Apoptosis; Cell Proliferation; Humans; Indoles; Melatonin; Membrane Potential, Mitochondrial; Nanost	2020
Melatonin and dopamine serum level associations with motor, cognitive, and sleep dysfunctions in patients with Parkinson's disease: A cross-sectional research study. NeuroRehabilitation, 2020, Volume: 46, Issue:4 Topics: Aged; Biomarkers; Cognition; Dopamine; Female; Humans; Male; Melatonin; Middle Aged; Parkinson Disea	2020
Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy. Sleep medicine, 2020, Volume: 75 Topics: Aged; Antiparkinson Agents; Circadian Rhythm; Cross-Sectional Studies; Humans; Levodopa; Melatonin;	2020
Melanopsin Cell Dysfunction is Involved in Sleep Disruption in Parkinson's Disease. Journal of Parkinson's disease, 2020, Volume: 10, Issue:4 Topics: Actigraphy; Aged; Chronobiology Disorders; Female; Humans; Male; Melatonin; Middle Aged; Parkinson D	2020
Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models. Neuropharmacology, 2021, 08-15, Volume: 194 Topics: alpha-Synuclein; Animals; Brain; Cell Line, Tumor; Female; Humans; Melatonin; Mice; Mice, Inbred BAL	2021
Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats. Journal of molecular neuroscience : MN, 2021, Volume: 71, Issue:4 Topics: Animals; Antiparkinson Agents; Brain; Male; Melatonin; Memory; Movement; Neurotransmitter Agents; Ox	2021
Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease. European journal of neurology, 2021, Volume: 28, Issue:6 Topics: Adult; Aged; Delayed-Action Preparations; Humans; Male; Melatonin; Nocturia; Parkinson Disease; Pilo	2021
Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease. Chinese medical journal, 2017, Nov-20, Volume: 130, Issue:22 Topics: Animals; Male; Melatonin; Oxidopamine; Parkinson Disease; Pars Compacta; Prefrontal Cortex; Rats; Ra	2017
Twenty Years After: Another Case Report of Melatonin Effects on REM Sleep Behavior Disorder, Using Serial Dopamine Transporter Imaging. Neuropsychobiology, 2017, Volume: 76, Issue:2 Topics: Aged; Brain; Central Nervous System Depressants; Dopamine Plasma Membrane Transport Proteins; Humans	2017
[Circadian Regulation and Its Disorders in Parkinson's Disease Patients. Part 2. Experimental Models, Alpha-Synuclein and Melatonin.] Fiziologiia cheloveka, 2016, Volume: 42, Issue:5 Topics: alpha-Synuclein; Circadian Rhythm; Dopamine; Humans; Melatonin; Parkinson Disease; Suprachiasmatic N	2016
Melatonin Improves Behavioral and Biochemical Outcomes in a Rotenone-Induced Rat Model of Parkinson's Disease. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2018, Volume: 37, Issue:2 Topics: Animals; Disease Models, Animal; Male; Melatonin; Muscle Strength; Neurotoxins; Neurotransmitter Age	2018
Melatonin Treatment of Visual Hallucinations in Parkinson Disease. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:5 Topics: Antioxidants; Hallucinations; Humans; Male; Melatonin; Middle Aged; Parkinson Disease	2018
[Correlations of Melatonin and Glutathione Levels with Oxidative Stress Mechanism in Parkinson's Disease]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2019, Apr-28, Volume: 41, Issue:2 Topics: Case-Control Studies; Cognitive Dysfunction; Glutathione; Humans; Melatonin; Oxidative Stress; Parki	2019
Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. Histology and histopathology, 2013, Volume: 28, Issue:8 Topics: alpha-Synuclein; Animals; Antioxidants; DNA, Complementary; Dopamine; Genetic Vectors; Green Fluores	2013
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep medicine, 2013, Volume: 14, Issue:8 Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective	2013
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep medicine, 2013, Volume: 14, Issue:8 Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective	2013
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep medicine, 2013, Volume: 14, Issue:8 Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective	2013
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep medicine, 2013, Volume: 14, Issue:8 Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective	2013
Serum melatonin is an alternative index of Parkinson's disease severity. Brain research, 2014, Feb-14, Volume: 1547 Topics: Aged; Aged, 80 and over; Animals; Apomorphine; Biomarkers; Dopamine Agonists; Female; Humans; Male;	2014
Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep medicine, 2014, Volume: 15, Issue:3 Topics: Actigraphy; Antiparkinson Agents; Case-Control Studies; Chronobiology Disorders; Female; Humans; Lev	2014
Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA neurology, 2014, Volume: 71, Issue:4 Topics: Aged; Biomarkers; Circadian Rhythm; Cohort Studies; Cross-Sectional Studies; Disorders of Excessive	2014
The central clock in patients with Parkinson disease. JAMA neurology, 2014, Volume: 71, Issue:11 Topics: Chronobiology Disorders; Circadian Rhythm; Disorders of Excessive Somnolence; Female; Humans; Male;	2014
The central clock in patients with Parkinson disease--reply. JAMA neurology, 2014, Volume: 71, Issue:11 Topics: Chronobiology Disorders; Circadian Rhythm; Disorders of Excessive Somnolence; Female; Humans; Male;	2014
Sleep-onset tome by actigraphy in patients with Parkinson's disease. Sleep medicine, 2015, Volume: 16, Issue:5 Topics: Chronobiology Disorders; Female; Humans; Male; Melatonin; Parkinson Disease	2015
Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation. Autophagy, 2015, Volume: 11, Issue:10 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Cyclin-Dependent	2015
Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease. Sleep medicine, 2015, Volume: 16, Issue:10 Topics: Animals; Antiparkinson Agents; Central Nervous System Depressants; Disease Models, Animal; Levodopa;	2015
Loss of REM sleep features across nighttime in REM sleep behavior disorder. Sleep medicine, 2016, Volume: 17 Topics: Adult; Aged; Chronobiology Disorders; Electromyography; Female; Humans; Male; Melatonin; Middle Aged	2016
Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:7 Topics: Aged; Female; Humans; Hypothalamus; Magnetic Resonance Imaging; Male; Melatonin; Middle Aged; Parkin	2016
Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a Drosophila model of Parkinson's disease. Molecular medicine reports, 2016, Volume: 13, Issue:5 Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Humans; Leu	2016
Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. Parkinsonism & related disorders, 2016, Volume: 29 Topics: Circadian Rhythm; Humans; Melatonin; Parkinson Disease	2016
Reply to letter: Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. Parkinsonism & related disorders, 2016, Volume: 29 Topics: Humans; Melatonin; Parkinson Disease; Sleep Wake Disorders; Wakefulness	2016
Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Journal of pineal research, 2011, Volume: 50, Issue:2 Topics: Animals; Blotting, Western; Cytochrome P-450 CYP2E1; Dopamine; Lipid Peroxidation; Male; Maneb; Mela	2011
Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB life, 2011, Volume: 63, Issue:12 Topics: Acetylcysteine; Antioxidants; Benzoquinones; DNA Adducts; Dopamine; Humans; Hydrogen-Ion Concentrati	2011
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat. Neurochemical research, 2012, Volume: 37, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression;	2012
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. Reviews in the neurosciences, 2012, Mar-01, Volume: 23, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Circadian Clocks; Combined Modality Therapy; D	2012
Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. Journal of pineal research, 2006, Volume: 40, Issue:3 Topics: Animals; Ascorbic Acid; Corpus Striatum; Dopamine; Levodopa; Light; Male; Melatonin; Microdialysis;	2006
Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. Journal of pineal research, 2007, Volume: 43, Issue:3 Topics: Animals; Behavior, Animal; Cell Line; Disease Models, Animal; Male; Melatonin; Neurons; Oxidopamine;	2007
Comment to the paper of Medeiros CAM, et al. (2007) J Neurol 254:459-464. Journal of neurology, 2008, Volume: 255, Issue:5 Topics: Antiparkinson Agents; Central Nervous System Depressants; Circadian Rhythm; Drug Administration Sche	2008
[Medical topics: sexual maturity and melatonin; Parkinson's disease]. [Kango] Japanese journal of nursing, 1984, Volume: 36, Issue:8 Topics: Humans; Melatonin; Parkinson Disease; Sexual Maturation	1984
Parkinsonian micrographia reversed by treatment with weak electromagnetic fields. The International journal of neuroscience, 1995, Volume: 81, Issue:1-2 Topics: Aged; Arm; Brain; Electromagnetic Phenomena; Humans; Leg; Male; Melatonin; Neurotransmitter Agents;	1995
Naltrexone attenuates the antiparkinsonian effects of picoTesla range magnetic fields. The International journal of neuroscience, 1994, Volume: 78, Issue:1-2 Topics: Adult; Electromagnetic Fields; Humans; Male; Melatonin; Naltrexone; Opioid Peptides; Parkinson Disea	1994
Reversal of micrographia in Parkinson's disease by application of picoTesla range magnetic fields. The International journal of neuroscience, 1994, Volume: 77, Issue:1-2 Topics: Electromagnetic Fields; Female; Humans; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland; Tre	1994
Weak magnetic fields antagonize the effects of melatonin on blood glucose levels in Parkinson's disease. The International journal of neuroscience, 1993, Volume: 68, Issue:1-2 Topics: Aged; Blood Glucose; Electromagnetic Fields; Humans; Male; Melatonin; Parkinson Disease; Pineal Glan	1993
Rapid improvement of visuoperceptive functions by picoTesla range magnetic fields in patients with Parkinson's disease. The International journal of neuroscience, 1993, Volume: 70, Issue:3-4 Topics: Dementia; Dopamine; Electromagnetic Fields; Humans; Male; Melatonin; Middle Aged; Parkinson Disease;	1993
The effects of external picoTesla range magnetic fields on the EEG in Parkinson's disease. The International journal of neuroscience, 1993, Volume: 70, Issue:1-2 Topics: Aged; Alpha Rhythm; Beta Rhythm; Brain Mapping; Electroencephalography; Electromagnetic Fields; Huma	1993
Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 5, Issue:3 Topics: Aged; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Movement Disorders;	1993
Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. Journal of pineal research, 1998, Volume: 24, Issue:3 Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; DNA Fragmentation; Melatonin; Neurons; Oxidopami	1998
Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats. Neuroscience letters, 1998, Apr-03, Volume: 245, Issue:2 Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Dopamine; Dopamine Agents; Female; Male; Melaton	1998
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiology & behavior, 1999, Volume: 66, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi	1999
On being a patient. To dream. Annals of internal medicine, 1999, Oct-05, Volume: 131, Issue:7 Topics: Caregivers; Dreams; Father-Child Relations; Humans; Melatonin; Parkinson Disease; Pineal Gland	1999
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:1 Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron	2001
Increased pineal Fdopa uptake is related to severity of Parkinson's disease--a PET study. Journal of pineal research, 2001, Volume: 30, Issue:4 Topics: Adult; Aromatic-L-Amino-Acid Decarboxylases; Biological Transport, Active; Case-Control Studies; Dih	2001
Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland. The International journal of neuroscience, 1992, Volume: 63, Issue:1-2 Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipmen	1992
Magnetic fields in the treatment of Parkinson's disease. The International journal of neuroscience, 1992, Volume: 63, Issue:1-2 Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipmen	1992
Fatigue and melatonin in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1991, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Fatigue; Female; Humans; Male; Melatonin; Middle Aged; Parkinson Dis	1991
Pineal melatonin functions and the depression of Parkinson's disease: a hypothesis. The International journal of neuroscience, 1990, Volume: 51, Issue:1-2 Topics: 5-Hydroxytryptophan; Animals; Depression; Dopamine; Humans; Melatonin; Models, Neurological; Parkins	1990
Accumulation of a parkinsonism-inducing neurotoxin in melanin-bearing neurons: autoradiographic studies on 3H-MPTP. Acta pharmacologica et toxicologica, 1986, Volume: 59, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Melatonin; Neurons; Neurotox	1986
Melatonin and parkinsonism. JAMA, 1972, Jul-03, Volume: 221, Issue:1 Topics: Dihydroxyphenylalanine; Drug Tolerance; Evaluation Studies as Topic; Humans; Melatonin; Parkinson Di	1972
On the effect of melatonin upon human brain. Its possible therapeutic implications. Life sciences. Pt. 1: Physiology and pharmacology, 1971, Aug-01, Volume: 10, Issue:15 Topics: Administration, Oral; Adolescent; Adult; Brain; Electroencephalography; Electrophysiology; Epilepsy;	1971

melatonin and Parkinson Disease

Research Excerpts

Research

Studies (124)

Authors

Clinical Trials (3)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Jiménez-Delgado, A	2
Ortiz, GG	2
Delgado-Lara, DL	2
González-Usigli, HA	1
González-Ortiz, LJ	1
Cid-Hernández, M	1
Cruz-Serrano, JA	2
Pacheco-Moisés, FP	1
Asefy, Z	1
Khusro, A	1
Mammadova, S	1
Hoseinnejhad, S	1
Eftekhari, A	1
Alghamdi, S	1
Dablool, AS	1
Almehmadi, M	1
Kazemi, E	1
Sahibzada, MUK	1
Endepols, H	1
Zlatopolskiy, BD	1
Zischler, J	1
Alavinejad, N	1
Apetz, N	1
Vus, S	1
Drzezga, A	1
Neumaier, B	1
Liguori, C	1
Fernandes, M	1
Cerroni, R	1
Ludovisi, R	1
Mercuri, NB	1
Stefani, A	1
Pierantozzi, M	1
Hadi, F	1
Agah, E	1
Tavanbakhsh, S	1
Mirsepassi, Z	1
Mousavi, SV	1
Talachi, N	1
Tafakhori, A	1
Aghamollaii, V	1
Jung, YJ	1
Choi, H	1
Oh, E	2
Asemi-Rad, A	1
Moafi, M	1
Aliaghaei, A	1
Abbaszadeh, HA	1
Abdollahifar, MA	1
Ebrahimi, MJ	1
Heidari, MH	1
Sadeghi, Y	1
Gergin, S	1
Kirazlı, Ö	1
Boracı, H	1
Yıldız, SD	1
Yananlı, HR	1
Şehirli, ÜS	1
Yoo, YM	1
Joo, SS	1
Tchekalarova, J	1
Tzoneva, R	1
Smilowska, K	1
van Wamelen, DJ	1
Bloem, BR	1
Guo, YL	1
Wei, XJ	1
Zhang, T	2
Sun, T	1
Dodet, P	1
Khezri, MR	1
Esmaeili, A	1
Ghasemnejad-Berenji, M	1
Gilat, M	1
Coeytaux Jackson, A	1
Marshall, NS	1
Hammond, D	1
Mullins, AE	1
Hall, JM	1
Fang, BAM	1
Yee, BJ	1
Wong, KKH	1
Grunstein, RR	2
Lewis, SJG	1
Rodrigues, LS	1
Fagotti, J	1
D S Targa, A	1
D Noseda, AC	1
L Ilkiwa, J	1
Chuproski, AP	1
W C Dorieux, F	1
D Dos Santos, P	1
M S Lima, M	1
Srivastava, AK	2
Roy Choudhury, S	1
Karmakar, S	2
Gonzalez, A	1
Vallée, A	2
Lecarpentier, Y	2
Guillevin, R	2
Vallée, JN	2
Daneshvar Kakhaki, R	1
Ostadmohammadi, V	1
Kouchaki, E	2
Aghadavod, E	1
Bahmani, F	1
Tamtaji, OR	2
J Reiter, R	1
Mansournia, MA	1
Asemi, Z	2
Ahn, JH	1
Kim, M	1
Park, S	1
Jang, W	1
Park, J	1
Cho, JW	1
Kim, JS	1
Youn, J	1
Hadoush, H	1
Lababneh, T	1
Banihani, SA	1
Al-Jarrah, M	1
Jamous, M	1
González-Enríquez, GV	1
Torres-Mendoza, BM	1
González-Usigli, H	1
Cárdenas-Bedoya, J	1
Macías-Islas, MA	1
de la Rosa, AC	1
Pacheco-Moisés, F	1
Chen, D	1
Lee, TH	1
Kataoka, H	1
Saeki, K	1
Kurumatani, N	1
Sugie, K	1
Obayashi, K	1
Feigl, B	1
Dumpala, S	1
Kerr, GK	1
Zele, AJ	1
Luo, F	1
Sandhu, AF	1
Rungratanawanich, W	1
Williams, GE	1
Akbar, M	1
Zhou, S	1
Song, BJ	1
Wang, X	1
Zuzuárregui, JRP	1
During, EH	1
Choudhury, SR	1
Tancheva, L	1
Lazarova, M	1
Saso, L	1
Kalfin, R	1
Stefanova, M	1
Uzunova, D	1
Atanasov, AG	1
Batla, A	1
Simeoni, S	1
Uchiyama, T	1
deMin, L	1
Baldwin, J	1
Melbourne, C	1
Islam, S	1
Bhatia, KP	1
Pakzad, M	1
Eriksson, S	1
Panicker, JN	1
Iranzo, A	3
Ramos, LA	1
Novo, S	1
St Louis, EK	1
Boeve, AR	1
Boeve, BF	2
Shen, Y	1
Guo, X	1
Han, C	1
Wan, F	1
Ma, K	1
Guo, S	1
Wang, L	1
Xia, Y	1
Liu, L	1
Lin, Z	1
Huang, J	1
Xiong, N	1
Wang, T	1
Li, Y	1
Wang, SM	1
Guo, L	1
Zhu, J	1
Wang, Y	1
Li, L	1
Zhao, YX	1
Arushanyan, EB	1
Naumov, SS	1
Kunz, D	1
Bes, F	1
Ukraintseva, YV	1
Kovalzon, VM	1
Rasheed, MZ	1
Andrabi, SS	1
Salman, M	1
Tabassum, H	1
Shaquiquzzaman, M	1
Parveen, S	1
Parvez, S	1
Delucca, BJ	1
Richardson, RM	1
Stewart, JT	1
Dauvilliers, Y	2
Schenck, CH	2
Postuma, RB	1
Luppi, PH	2
Plazzi, G	2
Montplaisir, J	1
Boeve, B	1
Wei, HJ	1
DU, M	1
Bai, HY	1
Reiter, RJ	2
Alipoor, R	1
Dadgostar, E	1
Brito-Armas, JM	1
Baekelandt, V	1
Castro-Hernández, JR	1
González-Hernández, T	1
Rodríguez, M	1
Castro, R	1
Montplaisir, JY	1
Frauscher, B	1
Hogl, B	1
Gagnon, JF	1
Postuma, R	1
Sonka, K	1
Jennum, P	1
Partinen, M	2
Arnulf, I	2
Cochen de Cock, V	1
Heidbreder, A	1
Mayer, G	1
Sixel-Döring, F	1
Trenkwalder, C	1
Unger, M	1
Young, P	1
Wing, YK	1
Ferini-Strambi, L	1
Ferri, R	1
Zucconi, M	1
Inoue, Y	1
Santamaria, J	1
Bassetti, C	1
Möller, JC	1
Lai, YY	1
Pavlova, M	1
Saper, C	1
Schmidt, P	1
Siegel, JM	1
Singer, C	1
St Louis, E	1
Videnovic, A	3
Oertel, W	1
Datieva, VK	1
Rosinskaia, AV	1
Levin, OS	1
Phillipson, OT	1
Lin, L	2
Du, Y	1
Yuan, S	1
Shen, J	1
Lin, X	1
Zheng, Z	1
Bolitho, SJ	1
Naismith, SL	1
Rajaratnam, SM	1
Hodges, JR	1
Terpening, Z	1
Rogers, N	1
Lewis, SJ	1
Noble, C	1
Reid, KJ	1
Peng, J	1
Turek, FW	1
Marconi, A	1
Rademaker, AW	1
Simuni, T	1
Zadikoff, C	1
Zee, PC	2
Fifel, K	1
DeBoer, T	1
Breen, DP	3
Barker, RA	3
Kawada, T	1
Su, LY	1
Li, H	1
Lv, L	1
Feng, YM	1
Li, GD	1
Luo, R	1
Zhou, HJ	1
Lei, XG	1
Ma, L	1
Li, JL	1
Xu, L	1
Hu, XT	1
Yao, YG	1
Belaid, H	1
Adrien, J	1
Karachi, C	1
Hirsch, EC	1
François, C	1
Arnaldi, D	1
Latimier, A	1
Leu-Semenescu, S	1
Vidailhet, M	1
Lim, Y	1
Cho, H	1
Kim, EK	1
Nombela, C	1
Vuono, R	1
Jones, PS	1
Fisher, K	1
Burn, DJ	1
Brooks, DJ	1
Reddy, AB	1
Rowe, JB	1
Sun, X	1
Ran, D	1
Zhao, X	1
Huang, Y	1
Long, S	1
Liang, F	1
Guo, W	1
Nucifora, FC	1
Gu, H	1
Lu, X	1
Chen, L	1
Zeng, J	1
Ross, CA	1
Pei, Z	1
Rodrigues, TM	1
Castro Caldas, A	1
Ferreira, JJ	1
Anderson, G	1
Seo, M	1
Berk, M	1
Carvalho, AF	1
Maes, M	1
Mack, JM	1
Schamne, MG	1
Sampaio, TB	1
Pértile, RA	1
Fernandes, PA	1
Markus, RP	1
Prediger, RD	1
Pillai, JA	1
Leverenz, JB	1
Willis, GL	4
Fernández-Tresguerres Hernández, JA	1
Lauterbach, EC	1
Victoroff, J	1
Coburn, KL	1
Shillcutt, SD	1
Doonan, SM	1
Mendez, MF	1
Singhal, NK	1
Srivastava, G	1
Patel, DK	1
Jain, SK	1
Singh, MP	1
Baksheev, VI	1
Kolomoets, NM	1
Zahid, M	1
Saeed, M	1
Yang, L	1
Beseler, C	1
Rogan, E	1
Cavalieri, EL	1
Meng, T	1
Zheng, ZH	1
Liu, TT	1
Cardinali, DP	2
Pagano, ES	1
Scacchi Bernasconi, PA	1
Reynoso, R	1
Scacchi, P	1
Moore, C	1
Armstrong, SM	2
Ylikoski, A	1
Litvinenko, IV	1
Krasakov, IV	1
Tikhomirova, OV	1
Serrano, C	1
García-Borreguero, D	1
Dowling, GA	1
Mastick, J	1
Colling, E	1
Carter, JH	1
Singer, CM	1
Aminoff, MJ	1
Srinivasan, V	1
Pandi-Perumal, SR	1
Maestroni, GJ	1
Esquifino, AI	1
Hardeland, R	1
Mayo, JC	2
Sainz, RM	2
Tan, DX	1
Antolín, I	2
Rodríguez, C	2
Rocchitta, G	1
Migheli, R	1
Esposito, G	1
Marchetti, B	1
Desole, MS	1
Miele, E	1
Serra, PA	1
Schernhammer, E	1
Chen, H	1
Ritz, B	1
Medeiros, CA	1
Carvalhedo de Bruin, PF	1
Lopes, LA	1
Magalhães, MC	1
de Lourdes Seabra, M	1
de Bruin, VM	1
Sharma, R	1
McMillan, CR	1
Niles, LP	1
Gugger, JJ	1
Wagner, ML	1
Fertl, E	3
Hadjiconstantinou, M	1
Neff, NH	1
Shibusawa, K	1
Sandyk, R	16
Iacono, RP	3
Derpapas, K	2
Auff, E	2
Doppelbauer, A	2
Waldhauser, F	2
Djamgoz, MB	1
Hankins, MW	1
Hirano, J	1
Archer, SN	1
Uria, H	1
Esteban, MM	1
Jin, BK	1
Shin, DY	1
Jeong, MY	1
Gwag, MR	1
Baik, HW	1
Yoon, KS	1
Cho, YH	1
Joo, WS	1
Kim, YS	1
Baik, HH	1
Epstein, N	1
Dabbeni-Sala, F	1
Franceschini, D	1
Skaper, SD	1
Giusti, P	1
Ghaemi, M	1
Rudolf, J	1
Hilker, R	1
Herholz, K	1
Heiss, WD	1
Zisapel, N	1
Shaw, KM	2
Anninos, PA	1
Tsagas, N	1
Critchley, PH	1
Malcolm, GP	1
Malcolm, PN	1
Gibb, WR	1
Arendt, J	1
Parkes, JD	1
Lindquist, NG	1
Lydén-Sokolowski, A	1
Larsson, BS	1
Stern, GM	1
Sandler, M	1
Antón-Tay, F	2
Cotzias, GC	2
Papavasiliou, PS	2
Ginos, J	1
Steck, A	1
Düby, S	1
Düby, SE	1
Steck, AJ	1
Bell, M	1
Lawrence, WH	1
Díaz, JL	1
Fernández-Guardiola, A	1